Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.
Nuvation Bio Inc. reports news as a global oncology company developing and commercializing targeted cancer therapies. Its updates center on IBTROZI® (taletrectinib), an oral, CNS-active, selective next-generation ROS1 inhibitor approved for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer, as well as regulatory submissions, clinical data from TRUST studies, guideline inclusion, and commercialization activity.
Company news also covers safusidenib, a brain-penetrant IDH1 inhibitor for IDH1-mutant glioma, and Nuvation Bio's drug-drug conjugate program. Recurring corporate items include licensing and collaboration arrangements, product-rights updates, investor conference participation, operating results, financial results, capital-structure disclosures, and governance matters.
Nuvation Bio Inc. (NYSE: NUVB) announced that the FDA granted Orphan Drug Designation for NUV-422, a CDK 2/4/6 inhibitor, aimed at treating malignant gliomas. This designation signifies support for drug development targeting rare disorders affecting fewer than 200,000 U.S. patients, qualifying NUV-422 for tax credits and seven years of market exclusivity upon approval. The Phase 1/2 study of NUV-422 is ongoing, focusing on safety and response rates in patients with high-grade gliomas, including glioblastoma. Data expected in 2022 underscores the drug's potential significance in addressing unmet medical needs.